大剂量阿糖胞苷治疗儿童急性髓系自血病的剂量耐受探讨  

The Tolerated Dose of High Dose Cytarabine in Childhood with Acute Myeloid Leukemia

作　　者：卫凤桂[1] 关镜明[1] 邹亚伟[1] 陈福雄[1] 吴梓梁[1] 

机构地区：[1]广州医学院第一附属医院,广东广州510120

出　　处：《医学信息》2013年第8期125-125,共1页Journal of Medical Information

摘　　要：目的探讨36g／m2阿糖胞苷治疗儿童急性髓系白血病的耐受情况。方法对比应用36g／m2与18g／m2阿糖胞苷，监测用药后血细胞计数、肝肾功能、感染指标、消化道及神经系统症状。结果应用36g/m2阿糖胞苷后粒细胞缺乏平均时间、发热天数均比应用18g/m2明显延长（14：7．5d，8：3d）；其余监测指标发生程度均较轻．无统计学差异。结论36g/m2阿糖胞苷应用于儿童急性髓系白血病可耐受。Objective To establish the tolerated dose 36g/m2 cytarabine treated in childhood with acute myeloid leukemia. Methods Compared with 36g/m2 and 18g/m2, blood cell counts, liver and renal function, infection index, gastrointestinal toxicity and central nervous system toxicity were observed. Results The median time of neutrophil deficiency and fever in childhood treated with 36g/m2 cytarabine are longer than treated with 18g/m2.（14：7.5 days, 8：3 days） Other toxicities are moderate. Conclusion 36g/m2 eytarabine is tolerated in childhood with acute myeloid leukemia.

关 键 词：阿糖胞苷 急性髓系白血病 

分 类 号：R733.7[医药卫生—肿瘤]